Passerini, V., Jurinovic, V., Tobin, J., Bantilan, K., Shelton, V., Richter, J., Okosun, J., Fitzgibbon, J., Klapper, W., Davies, A., Marcus, R., Herold, M., Hiddemann, W., Unterhalt, M., Detroja, R., Nelles, R., Lawrence, P., Hapgood, G., Cochrane, T., Johnston, A., Royle, J., Manos, K., Barraclough, A., Cheah, C., Hawkes, E., Hodges, G., Shortt, J., Talaulikar, D., Trotman, J., Morris, K., Gutta, N., Bottos, A., Dreyling, M., Gandhi, M., Kridel, R., Zelenetz, A., Hoster, E., Weigert, O. (2025). EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort. Blood. https://doi.org/10.1182/blood-2025-52